Lymphoedema - Pipeline Insight, 2024

This “Lymphoedema- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lymphoedema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Lymphoedema: Understanding

Lymphoedema: Overview

Lymphoedema is a chronic disease marked by the increased collection of lymphatic fluid in the body, causing swelling, which can lead to skin and tissue changes. The chronic, progressive accumulation of protein-rich fluid within the interstitium and the fibro-adipose tissue exceeds the capacity of the lymphatic system to transport the fluid.

Symptoms
The symptoms of Lymphoedema include:

• Distal swelling in the extremities including the arms, hands, legs, feet; swelling proximally in the breast, chest, shoulder, pelvis, groin, genitals, face/intraoral tissues
• Restricted range of motion in the joints because of swelling and tissue changes
• Skin discoloration
• Pain and altered sensation
• Limb heaviness;
• Difficulty fitting into clothing

Diagnosis
Lymphedema is often confused with other causes of extremity edema and enlargement. Diagnosis is suspected by evaluating the history and physical examination. Lymphoscintigraphy confirms the diagnosis. Imaging is unnecessary to make the diagnosis but can be used as confirmation, assessment of the extent of involvement, and help to determine therapeutic intervention. Newer technologies include 3-dimensional magnetic resonance imaging (MRI), computerized tomography (CT), ultrasound, and bioelectrical impedance analysis. Ultrasound is useful to exclude other etiologies like DVT, venous insufficiency and can also help in identifying tissue changes and masses that might be the cause of lymphatic compression. CT and MRI can investigate soft tissue edema with good sensitivity and specificity, but they are relatively expensive.

Treatment
Lymphedema is a progressive disease, and early diagnosis and treatment are paramount. Critical to diagnose and treat both mild and early onset cases to halt the progression of this lifelong and often debilitating condition. For patients to improve their knowledge base and learn helpful evidence-based management and coping strategies, patients must be referred to a specialist holding certification in lymphedema treatment and management eg.physician, an occupational therapist, or physical therapist. Decongestive lymphedema therapy (DLT): Is the primary treatment for moderate-to-severe lymphedema and mobilizes lymph and dissipate fibrosclerotic tissue. Manual lymph drainage (MLD): Light lymph massage designed to increase lymph flow. Compression: Helps with drainage but can increase the risk of infection. Skincare: Fastidious skin care is essential to prevent secondary skin infections. Exercise: Light exercise promotes lymph drainage and protein absorption via muscle contraction. Drug therapy acts as adjunctive only for pain control or secondary infection.

Lymphoedema- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lymphoedema pipeline landscape is provided which includes the disease overview and Lymphoedema treatment guidelines. The assessment part of the report embraces, in depth Lymphoedema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lymphoedema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lymphoedema R&D. The therapies under development are focused on novel approaches to treat/improve Lymphoedema.

Lymphoedema Emerging Drugs Chapters

This segment of the Lymphoedema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lymphoedema Emerging Drugs

Lymfactin: Herantis Pharma Lymfactin is currently in Phase II trial of clinical study. It is being developed by Herantis Pharma. Lymfactin is derived from the scientific discovery of Vascular Endothelial Growth Factor C (VEGF-C), the natural human protein necessary for the growth of new lymphatic vessels. It is a gene therapy product, which delivers the human gene coding for VEGF-C and thereby promotes the formation of new lymphatic vessels. Lymfactin is administered locally at the damaged site of the lymphatic system with the aim of repairing thoseinjuries.

Lymphoedema: Therapeutic Assessment

This segment of the report provides insights about the different Lymphoedema drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lymphoedema

There are approx. 10+ key companies which are developing the therapies for Lymphoedema. The companies which have their Lymphoedema drug candidates in the most advanced stage, i.e. phase II include, Herantis Pharma.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Lymphoedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lymphoedema: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lymphoedema therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lymphoedema drugs.

Lymphoedema Report Insights

• Lymphoedema Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lymphoedema Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lymphoedema drugs?
• How many Lymphoedema drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lymphoedema?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lymphoedema therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lymphoedema and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Herantis Pharma
• AnGes
• Pure TechHealth

Key Products

• Lymfactin
• Beperminogene perplasmid
• Deupirfenidone

This product will be delivered within 1-3 business days.